| Literature DB >> 27213367 |
Nadjet Rezki1,2, Salsabeel A Al-Sodies3, Mohamed R Aouad4,5, Sanaa Bardaweel6, Mouslim Messali7, El Sayed H El Ashry8.
Abstract
The present work reports an efficient synthesis of fluorinated pyridinium salts-based hydrazones under both conventional and eco-friendly ultrasound procedures. The synthetic approach first involves the preparation of halogenated pyridinium salts through the condensation of isonicotinic acid hydrazide (1) with p-fluorobenzaldehyde (2) followed by the nucleophilic alkylation of the resulting N-(4-fluorobenzylidene)isonicotinohydrazide (3) with a different alkyl iodide. The iodide counteranion of 5-10 was subjected to an anion exchange metathesis reaction in the presence of an excess of the appropriate metal salts to afford a new series of fluorinated pyridinium salts tethering a hydrazone linkage 11-40. Ultrasound irradiation led to higher yields in considerably less time than the conventional methods. The newly synthesized ILs were well-characterized with FT-IR, ¹H NMR, (13)C NMR, (11)B, (19)F, (31)P and mass spectral analyses. The ILs were also screened for their antimicrobial and antitumor activities. Within the series, the salts tethering fluorinated counter anions 11-13, 21-23, 31-33 and 36-38 were found to be more potent against all bacterial and fungal strains at MIC 4-8 µg/mL. The in vitro antiproliferative activity was also investigated against four tumor cell lines (human ductal breast epithelial tumor T47D, human breast adenocarcinoma MCF-7, human epithelial carcinoma HeLa and human epithelial colorectal adenocarcinoma Caco-2) using the MTT assay, which revealed that promising antitumor activity was exhibited by compounds 5, 12 and 14.Entities:
Keywords: anticancer activity; antimicrobial activity; hydrazones; metathesis; ultrasound irradiation
Mesh:
Substances:
Year: 2016 PMID: 27213367 PMCID: PMC4881586 DOI: 10.3390/ijms17050766
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Scheme 1Synthesis of halogenated pyridinium salts tagged with hydrazone 5–10 under conventional method (CM) and ultrasound irradiation (US).
Conventional versus ultrasound times and yields of hydrazone 3 and pyridinium salts 5–10.
| Compound No. | R | Conventional Method | Ultrasound Method | ||
|---|---|---|---|---|---|
| Time (h) | Yield (%) | Time (h) | Yield (%) | ||
| – | 1 | 90 | 0.5 | 96 | |
| C2H5 | 72 | 85 | 12 | 94 | |
| C3H7 | 72 | 83 | 12 | 93 | |
| C4H9 | 72 | 85 | 14 | 90 | |
| C5H11 | 72 | 91 | 14 | 94 | |
| C6H13 | 72 | 86 | 14 | 92 | |
| C7H15 | 72 | 91 | 14 | 94 | |
Figure 11H NMR spectrum of compound 9 in DMSO-d6.
Figure 21H NMR spectrum of compound 9 in CDCl3.
Figure 319F NMR spectrum of compound 9 in DMSO-d6.
Scheme 2Synthesis of specific-based hydrazones 11–40.
Conventional versus ultrasound times and yields of compounds 11–40.
| Compound No. | R | Y | Conventional Method | Ultrasound Method | ||
|---|---|---|---|---|---|---|
| Time (h) | Yield (%) | Time (h) | Yield (%) | |||
| C2H5 | PF6 | 16 | 94 | 6 | 98 | |
| C2H5 | BF4 | 16 | 85 | 6 | 92 | |
| C2H5 | COOCF3 | 16 | 80 | 6 | 90 | |
| C2H5 | NO3 | 16 | 89 | 5 | 98 | |
| C2H5 | SCN | 16 | 98 | 6 | 98 | |
| C3H7 | PF6 | 16 | 93 | 6 | 96 | |
| C3H7 | BF4 | 16 | 81 | 6 | 90 | |
| C3H7 | COOCF3 | 16 | 85 | 6 | 94 | |
| C3H7 | NO3 | 16 | 82 | 5 | 92 | |
| C3H7 | SCN | 16 | 85 | 5 | 96 | |
| C4H9 | PF6 | 16 | 88 | 6 | 94 | |
| C4H9 | BF4 | 16 | 83 | 6 | 90 | |
| C4H9 | COOCF3 | 16 | 85 | 6 | 92 | |
| C4H9 | NO3 | 16 | 83 | 5 | 90 | |
| C4H9 | SCN | 16 | 83 | 5 | 92 | |
| C5H11 | PF6 | 16 | 86 | 6 | 94 | |
| C5H11 | BF4 | 16 | 90 | 6 | 98 | |
| C5H11 | COOCF3 | 16 | 80 | 6 | 92 | |
| C5H11 | NO3 | 16 | 94 | 5 | 98 | |
| C5H11 | SCN | 16 | 96 | 5 | 98 | |
| C6H13 | PF6 | 16 | 91 | 6 | 98 | |
| C6H13 | BF4 | 16 | 98 | 6 | 98 | |
| C6H13 | COOCF3 | 16 | 89 | 6 | 92 | |
| C6H13 | NO3 | 16 | 87 | 5 | 94 | |
| C6H13 | SCN | 16 | 98 | 5 | 98 | |
| C7H15 | PF6 | 16 | 98 | 6 | 98 | |
| C7H15 | BF4 | 16 | 98 | 6 | 98 | |
| C7H15 | COOCF3 | 16 | 80 | 6 | 88 | |
| C7H15 | NO3 | 16 | 83 | 6 | 88 | |
| C7H15 | SCN | 16 | 80 | 6 | 86 | |
Antimicrobial activity expressed as MIC (μg/mL).
| Compound No. | Gram-Positive Organisms | Gram-Negative Organisms | Fungi | |||||
|---|---|---|---|---|---|---|---|---|
| 16 | 16 | 16 | 16 | 16 | 16 | 125 | 125 | |
| 16 | 16 | 16 | 16 | 16 | 16 | 62.5 | 125 | |
| 8 | 8 | 16 | 16 | 8 | 8 | 62.5 | 62.5 | |
| 8 | 8 | 8 | 16 | 8 | 8 | 62.5 | 62.5 | |
| 8 | 4 | 4 | 8 | 8 | 8 | 31.25 | 31.25 | |
| 8 | 4 | 8 | 4 | 8 | 8 | 16 | 16 | |
| 4 | 4 | 8 | 16 | 16 | 16 | 31.25 | 31.25 | |
| 16 | 16 | 16 | 16 | 16 | 16 | 125 | 125 | |
| 16 | 16 | 16 | 16 | 16 | 16 | 250 | 250 | |
| 8 | 4 | 4 | 8 | 8 | 8 | 31.25 | 31.25 | |
| 8 | 4 | 4 | 4 | 8 | 8 | 31.25 | 31.25 | |
| 4 | 4 | 8 | 8 | 8 | 8 | 16 | 16 | |
| 16 | 16 | 16 | 16 | 16 | 16 | 125 | 125 | |
| 16 | 16 | 16 | 16 | 16 | 16 | 125 | 125 | |
| 8 | 8 | 4 | 8 | 8 | 8 | 16 | 16 | |
| 4 | 4 | 4 | 8 | 4 | 4 | 16 | 16 | |
| 4 | 4 | 4 | 4 | 4 | 4 | 8 | 8 | |
| 8 | 8 | 8 | 8 | 4 | 8 | 125 | 125 | |
| 8 | 8 | 8 | 8 | 4 | 8 | 125 | 125 | |
| 4 | 4 | 4 | 4 | 4 | 4 | 16 | 16 | |
| 4 | 4 | 4 | 4 | 4 | 4 | 8 | 8 | |
| 4 | 4 | 4 | 4 | 4 | 4 | 8 | 8 | |
| 4 | 4 | 8 | 4 | 4 | 8 | 125 | 125 | |
| 4 | 4 | 8 | 4 | 4 | 8 | 125 | 125 | |
| ≤5 | ≤1 | ≤5 | ≤5 | ≤1 | ≤1 | – | – | |
| – | – | – | – | – | – | ≤1 | ≤1 | |
LD50 values (ng/µL) of the examined compounds on four human cancer cell lines. Values are expressed as the mean ± SD of three experiments.
| Compound No. | MCF-7 | T47D | HeLa | Caco-2 |
|---|---|---|---|---|
| 286 ± 8 | 278 ± 10 | 292 ± 9 | 301 ± 11 | |
| Not active | Not active | Not active | Not active | |
| 512 ± 11 | 498 ± 6 | 503 ± 8 | 528 ± 10 | |
| Not active | Not active | Not active | Not active | |
| 465 ± 8 | 486 ± 13 | 471 ± 15 | 463 ± 9 | |
| Not active | Not active | Not active | Not active |
Human ductal breast epithelial tumor T47D; Human breast adenocarcinoma MCF-7; Human epithelial carcinoma HeLa; Human epithelial colorectal adenocarcinoma Caco-2.